Bragar Eagel & Squire, P.C. is investigating potential claims against Trinity Biotech plc (NASDAQ:TRIB) concerning possible violations of the federal securities laws. On October 4, 2016, Trinity revealed that it was withdrawing its 510(k) premarket notification submission for the Meritas Troponin-I Test and Meritas Point-of-Care Analyzer, following the U.S. Food and Drug Administration's advice. Trinity also said it would decrease its spending by roughly 85%, from $9 million each year to $1.5 million, and that it would close its Swedish facility, eliminating 40 jobs. Following this news, Trinity shares dropped $6.53 per share to close at $6.46 on October 4, 2016. If you purchased or otherwise acquired Trinity securities and suffered a loss, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact J. Brandon Walker, Esq. by email at email@example.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Trinity Biotech plc, please go to www.bespc.com/trinity-biotech-plc. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.